Haemonetics (HAE) to Release Earnings on Thursday

Haemonetics (NYSE:HAE) is expected to be announcing its Q3 2026 results before the market opens on Thursday, February 5th. Analysts expect the company to announce earnings of $1.27 per share and revenue of $331.8980 million for the quarter. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. Interested persons can find conference call details on the company’s upcoming Q3 2026 earning report page for the latest details on the call scheduled for Thursday, February 5, 2026 at 8:00 AM ET.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 EPS for the quarter, topping analysts’ consensus estimates of $1.12 by $0.15. Haemonetics had a return on equity of 27.22% and a net margin of 12.67%.The firm had revenue of $327.32 million during the quarter, compared to analyst estimates of $311.61 million. During the same period last year, the company earned $1.12 earnings per share. The business’s revenue for the quarter was down 5.3% on a year-over-year basis. On average, analysts expect Haemonetics to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Haemonetics Stock Performance

NYSE:HAE opened at $64.67 on Wednesday. The business’s fifty day moving average is $77.88 and its 200 day moving average is $65.27. The firm has a market cap of $3.03 billion, a price-to-earnings ratio of 18.91, a PEG ratio of 1.37 and a beta of 0.28. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.03 and a current ratio of 1.64. Haemonetics has a 52-week low of $47.31 and a 52-week high of $87.32.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Mizuho upped their price target on Haemonetics from $75.00 to $90.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Raymond James Financial reaffirmed an “outperform” rating and set a $90.00 target price on shares of Haemonetics in a report on Friday, November 14th. Weiss Ratings reissued a “hold (c)” rating on shares of Haemonetics in a report on Monday, December 29th. Barrington Research restated an “outperform” rating and set a $93.00 price target on shares of Haemonetics in a research report on Monday. Finally, CJS Securities upgraded Haemonetics to a “strong-buy” rating in a research report on Thursday, December 11th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $84.40.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC raised its position in Haemonetics by 2,640.0% during the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 396 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Haemonetics by 20,925.0% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 841 shares of the medical instruments supplier’s stock worth $41,000 after purchasing an additional 837 shares in the last quarter. CIBC Private Wealth Group LLC increased its position in shares of Haemonetics by 69.3% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,094 shares of the medical instruments supplier’s stock valued at $53,000 after purchasing an additional 448 shares during the last quarter. Quadrant Capital Group LLC bought a new position in shares of Haemonetics during the 3rd quarter valued at about $76,000. Finally, Strs Ohio purchased a new position in shares of Haemonetics during the 1st quarter valued at about $140,000. Institutional investors own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.